home Go to Doctors Page
ScienceBased Health
1 888 433 4726
  • Doctor
  • Consumer
Facebook Twitter

Free Shipping with Auto-Delivery & Savings up to 20% with a Package Plan

more +
Auto-Delivery & Free Shipping!
Save money and add convenience! Your product(s) will be automatically sent to you each month
Select the "Auto Delivery" box at checkout.
Save Packages:
Save up to 20% & Free Shipping!
Purchase 3-5 bottles: save 5%
Purchase 6-11 bottles: save 12%
Purchase 12+ bottles: save 20%

phone

Menu
  • Products
    • Products A-Z
    • Dry Eye
    • Eye & Whole Body Health
      • OcularProtect® Robust Whole Body Formula
      • OcularEssentials® Whole Body Formula
    • Macular Health Concerns
      • MacularProtect Complete® AREDS-Based Formula & Multinutrient
      • MacularProtect® AREDS-Based Formula
    • Omega-3
    • Optic Nerve Health
    • Retinal Circulation
    • Bone & Joint Health
      • BoneProtect
      • JointProtect
  • Faqs
  • Resources
    • Staying Healthy Newsletter
    • EduFacts Newsletter
    • Product Monographs
    • Educational Links
  • About us
    • Company
    • Advisory Boards
    • Press Releases
    • In the News
    • Events
  • Contact
  • Login
  • View Cart
  • (0)
Facebook Twitter

Supplemental GLA Improves Dry Eye in Sjögren's Syndrome

Inflammation and Sjögren's Syndrome

Affecting more than 1.4 million Americans, Sjögren's syndrome is an autoimmune disorder in which immune cells attack and destroy the glands that produce tears and saliva. The hallmark symptoms of the disorder are dry mouth and dry eyes. Sjögren's syndrome is also frequently associated with rheumatic disorders such as rheumatoid arthritis.

T-cell infiltration and markers of immune activation have been noted in both the conjunctiva and lacrimal glands of these patients. Topical anti-inflammatory treatment of patients with dry eye reportedly produces a significant reduction of activated lymphocyte in the conjunctiva, thus demonstrating the potential for anti-inflammatory treatment of dry eyes.

Anti-inflammatory Activity of GLA

Gamma-linolenic acid (GLA) and its precursor linoleic acid (LA) are essential fatty acids found in certain plant seed oils such as black currant seed oil. Oral administration of GLA and LA has been shown to have beneficial effects in the treatment of chronic inflammatory disorders such as rheumatoid arthritis, and several pilot studies conducted in the 1980's suggest that these fatty acids may also benefit the ocular status of patients with Sjögren's.

GLA is metabolized to dihomo-linolenic acid (DGLA), the immediate precursor of PGE1, an eicosanoid with known anti-inflammatory action. In addition, both GLA and DGLA modulate the immune responses by acting directly on T lymphocytes. Researchers from the University of Messina in Italy now report that modest amounts of supplemental GLA and LA raise PGE1 tear content in Sjögren's, and improve signs and symptoms of ocular discomfort in these patients.

Design and Methods

This randomized, double-blind, controlled trial involved 40 patients with primary Sjögren's Syndrome divided into 2 groups. One group received GLA (15 mg) and LA (112 mg) twice daily for 1 month (GLA group), while the other group received placebos. Subjects underwent 3 examinations: baseline (T0), after 1 month (T1), and 15 days after treatment was suspended (T2). At each exam, the following tests were performed: tear sampling from the inferior meniscus, TBUT, fluorescein stain of the ocular surface, and tear basal secretion. A symptom score was also obtained each time. PGE1 was evaluated by enzyme immunoassay, and PGE1 content of tears was the primary endpoint.

Results

Tear PGE1 levels were significantly increased in the GLA group after 1 month of treatment. Fifteen days after treatment was halted, a significant reduction of the PGE1 levels toward baseline was observed. The symptom score was significantly lower in the GLA group after 1 month, with several symptoms (burning, foreign body sensation and dryness) remaining improved after treatment was stopped. The corneal fluorescein stain in this group also showed a significant improvement after the first month, which was sustained 15 days after treatment cessation.

No statistically significant differences were found for the other tests. In contrast to the GLA group, no statistically significant changes were noted in the placebo group at all examination time points. These results are summarized in the table below (group 1 = supplemented; group 2 = placebo).

Conclusions

According to the authors, these results indicate that supplemental GLA and LA effectively increases PGE1, an indicator of anti-inflammatory activity, improves ocular surface status and reduces dry eye symptoms.

Reference
Aragona P, et al. Systemic omega-6 essential fatty acid treatment and PGE1 tear content in Sjogren's syndrome patients. Invest Ophthalmol Vis Sci 46:4474-9, 2005.

Home  >  General Webpages  >  Resources  >  Edufacts Content  >  EduFacts Scientific Write-ups  > 

Stay Informed

Sign up to get nutrition news, health tips, and product updates.

Please also send me:
EduFacts scientific write-ups (monthly)
Notice of new products and special offers

Your information is never shared with third parties. View our privacy policy

Like Us on Facebook

Follow SBH on Facebook for great health tips, product info and much more.

Our Quality Guarantee

  • Products meet or exceed new GMPs
  • Produced in NSF®-certified facilities
  • Highest quality raw materials utilized
  • Third party testing
  • 30-day money-back guarantee (60 days for HydroEye)
Learn more »

Innovative Nutraceuticals for Eye Health

ABOUT SSL
CERTIFICATES

This site chose VeriSign SSL
for secure e-commerce and
confidential communications.

Home | Feedback | Manufacturing | Privacy Policy | Terms & Conditions | Contact Us

Call us Toll Free 1.888.433.4726. From Outside the US and Canada 281.885.7700
©ScienceBased Health

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

Top